Expert view: Bio-Rad’s comprehensive genomics portfolio provides answers for every problem
Over three decades, Bio-Rad has built a broad genomics portfolio that touches on nearly every area of life science.
List view / Grid view
Over three decades, Bio-Rad has built a broad genomics portfolio that touches on nearly every area of life science.
A team has used a lentiviral capsid-based bionanoparticle system to deliver CRISPR-Cas9 gene editing therapies, reducing undesired effects.
The UK Biobank, the world’s largest genetics project, will sequence 500,000 genetic samples, which will be available to researchers everywhere.
Researchers have developed a new treatment method which turned glial cells into functioning neurons in mice after stroke.
A ground-breaking nervous system discovery could be significant for the treatment of different neurological diseases.
In this In-Depth Focus are articles on how genomics could revolutionise clinical treatment and an insight into the promise and pitfalls of using CRISPR.
A study has used a proteomic method to uncover why some melanoma tumours do not respond to immunotherapy, which could improve treatments.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
Researchers discover that a non-coding region of the genome originates a key molecule for the proliferation of cancerous tumours.
A compound that promotes the rebuilding of the protective sheath around nerve cells damaged in multiple sclerosis has been developed.
New gene mutation discovery could lead to more rapid and effective therapies for tuberculosis.
The UK Brain Banks Network has been enhanced to include genomic data, which can be accessed by researchers worldwide.
A protein that causes pancreatic ductal adenocarcinoma has been identified as a therapeutic target by researchers.
Researchers have mapped a previously uncharted region of the human genome which could lead to tests for certain conditions in the future.
A potential target for ALS has been revealed by a study which found the Fos-B gene encouraged axonal branching.